Literature DB >> 24731748

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

Willemijn van den Ancker1, Marvin M van Luijn1, Martine E D Chamuleau1, Angèle Kelder1, Nicole Feller1, Monique Terwijn1, Adri Zevenbergen1, Gerrit-Jan Schuurhuis1, S Marieke van Ham2, Theresia M Westers1, Gert J Ossenkoppele1, Arjan A van de Loosdrecht3.   

Abstract

The presence of class II-associated invariant chain (CLIP) on leukemic cells is negatively associated with clinical outcome in untreated acute myeloid leukemia (AML). CLIP plays a role in the immune escape of leukemic cells, suggesting that it impairs the immunogenicity of minimal residual disease (MRD) cells causing a relapse. Here, we demonstrate that CLIP expression on leukemia-associated phenotype (LAP)-positive cells during follow-up is significantly correlated with a shortened relapse-free survival, even in those patients who are generally considered as MRD(low) (0.01-0.1% LAP(+) cells). Consequently, CLIP evaluation could be of additional value in the evaluation of MRD to predict a relapse of AML.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD4(+) T cells; HLA; Immune escape; Leukemia-associated phenotype; Minimal residual disease

Mesh:

Substances:

Year:  2014        PMID: 24731748     DOI: 10.1016/j.leukres.2014.03.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

Review 1.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.

Authors:  Marvin M van Luijn; Willemijn van den Ancker; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

Review 3.  MRD in AML: does it already guide therapy decision-making?

Authors:  Gert Ossenkoppele; Gerrit Jan Schuurhuis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia.

Authors:  Kateřina Kuželová; Barbora Brodská; Jana Marková; Martina Petráčková; Johannes Schetelig; Šárka Ransdorfová; Zdenka Gašová; Cyril Šálek
Journal:  Oncoimmunology       Date:  2022-05-06       Impact factor: 7.723

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.